We are live on ! Find out more
BBOT

BridgeBio Oncology
BBOT

67 hedge funds and large institutions have $514M invested in BridgeBio Oncology in 2026 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 7

82% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 11

26% more funds holding

Funds holding: 53 → 67 (+14)

1.08% less ownership

Funds ownership: 72.9% → 71.82% (-1.1%)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

32% less capital invested

Capital invested by funds: $756M → $514M (-$242M)

Holders
67
Holders Change
+14
Holders Change %
+26.42%
% of All Funds
0.82%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.05%
New
23
Increased
20
Reduced
11
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
+$6.83M
2
LCM
Laurion Capital Management
New York
+$4.91M
3
ACM
Aisling Capital Management
New York
+$4.87M
4
AC
Armistice Capital
New York
+$3.52M
5
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$3.45M

Top Sellers

Rank Fund Capital Flow
1
CCM
Catalio Capital Management
New York
-$31.4M
2
PBA
Paradigm Biocapital Advisors
New York
-$15M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$10.7M
4
EAM
Eventide Asset Management
Massachusetts
-$5.81M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$2.38M +$263K +24,539 +10%
VFT
27
Vanguard Fiduciary Trust
Pennsylvania
$2.28M +$2.73M +254,329 New
Schroder Investment Management Group
28
Schroder Investment Management Group
United Kingdom
$2.16M +$2.68M +249,161 New
Fidelity Investments
29
Fidelity Investments
Massachusetts
$2.15M – – –
GIM
30
Granahan Investment Management
Massachusetts
$2.07M +$2.48M +231,040 New
State Street
31
State Street
Massachusetts
$2.03M +$85.9K +8,000 +4%
Goldman Sachs
32
Goldman Sachs
New York
$1.5M +$783K +72,922 +77%
SCM
33
Sio Capital Management
New York
$1.17M – – –
Hudson Bay Capital Management
34
Hudson Bay Capital Management
Connecticut
$985K +$1.18M +110,000 New
WP
35
Woodline Partners
California
$928K – – –
Northern Trust
36
Northern Trust
Illinois
$915K +$475K +44,224 +76%
Renaissance Technologies
37
Renaissance Technologies
New York
$912K +$296K +27,600 +37%
MCM
38
Moore Capital Management
New York
$895K – – –
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$813K +$691K +64,347 +243%
APM
40
Avidity Partners Management
Texas
$761K +$942K +87,706 New
TE
41
Tema ETFs
New York
$735K +$882K +82,172 New
TI
42
Tidal Investments
Wisconsin
$735K +$882K +82,172 New
BFM
43
Boothbay Fund Management
New York
$724K +$149K +13,850 +21%
HS
44
HighVista Strategies
Massachusetts
$700K -$1.62M -151,076 -66%
Qube Research & Technologies (QRT)
45
Qube Research & Technologies (QRT)
United Kingdom
$644K +$386K +35,973 +100%
XT
46
XTX Topco
Cayman Islands
$535K +$334K +31,110 +109%
TD Asset Management
47
TD Asset Management
Ontario, Canada
$515K -$640K -59,578 -51%
OM
48
Opaleye Management
Massachusetts
$477K +$572K +53,282 New
UBS Group
49
UBS Group
Switzerland
$452K -$461K -42,919 -46%
ECM
50
ExodusPoint Capital Management
New York
$431K +$517K +48,122 New
1
2
3

BBOT Hedge Fund Activity: Q1 2026 in Review

67 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q1 2026, worth a combined $514M — down 32% from $756M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new BBOT positions and 7 closed out — a net gain of 16 holders — while 20 added to existing stakes and 11 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $6.83M. The largest seller was Catalio Capital Management, exiting entirely with an estimated $31.4M sold.

  • 67 institutional investors held BridgeBio Oncology (BBOT) as of Q1 2026, up from 53 in Q4 2025.
  • Funds reported $514M of BridgeBio Oncology stock for Q1 2026, down 32% quarter-over-quarter.
  • 23 funds opened new BridgeBio Oncology positions in Q1 2026 and 7 closed out, a net change of +16 holders.
  • The largest BridgeBio Oncology buyer in Q1 2026 was Royce & Associates, an estimated $6.83M added.
  • The largest BridgeBio Oncology seller in Q1 2026 was Catalio Capital Management, an estimated $31.4M sold.

Based on aggregated 13F filings for Q1 2026.